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UNTUK KEGUNAAN DIAGNOSIS 
 
ABSTRAK 
 
panLF Rapid™ merupakan satu ujian pantas pengesanan antibodi IgG4 
berdasarkan pada pengesanan antibodi anti-filarial IgG4 yang bertindak balas dengan 
antigen rekombinan B. malayi, BmR1 dan BmSXP. Kit diagnostik ini adalah sangat 
berguna untuk pengesanan limfatik filariasis (LF), terutamanya dalam membantu 
WHO dalam aktiviti sertifikasi dan pengawasan pasca-pemberian ubat secara 
besar-besaran selari dengan usaha Program Penghapusan LF Sedunia atau ‘Global 
Programme to Eliminate Lymphatic Filariasis’. Pengeluaran kit ujian ini telah 
menerima permintaan yang ketara di pasaran, maka peningkatan penghasilan ke skala 
besar dan peningkatan efisiensi penulenan adalah perlu untuk meningkatkan kadar 
pengeluaran dan juga mengurangkan kos pengeluaran secara besar-besaran. Dalam 
kajian ini hasil BmSXP antigen rekombinan telah dimaksimumkan melalui 
penghasilan biomass yang tinggi dengan menggunakan kultur sekelompok di dalam 
bioreaktor, dan tahap pemulihan protein sasaran ini telah dioptimumkan melalui 
proses penulenan hiliran. Pengkulturan bakteria rekombinan 
(TOP10F’/pPROEX™HTa/BmSXP) pada awalnya telah dioptimumkan dalam 
fermentasi berskala kecil dengan menggunakan kelalang goncang di mana ia 
menghasilkan 4.2 g.L-1 dan 0.576 mg.g DCW-1 antigen rekombinan BmSXP. Proses 
 xxiii 
penaikkan-skala kemudian dijalankan dengan menggunakan kaedah fermentasi 
kultur sekelompok di mana sel ditumbuhkan di dalam media kaldu Terrifc broth 
terubahsuai dan glukosa disuapkan secara eksponen pada kadar yang terkawal 
menggunakan ‘Multifermenter Control Software’ (MFCS) untuk suapan secara 
automatik. Dengan mempelbagaikan strategi suapan kadar pertumbuhan spesifik (µ) 
dan strategi induksi, hasil biomass sebanyak 19.43 g.L-1 dan 11.16 mg.g DCW-1 
antigen rekombinan BmSXP telah diperolehi hasil daripada strategi suapan secara 
eksponen pada µ sebanyak 0.20 h-1, dan dengan aruhan tunggal 1 mM IPTG pada 
akhir fasa log pertengahan pertumbuhan bakteria. Selain itu juga, dapat dilihat 
bahawa pada kadar suapan ini, pekali fermentasi hasil produktiviti (YP/X), hasil 
biomass (YX/S) dan hasil produk (YP/S) adalah tinggi. Strategi ini telah berjaya 
mengawal pengumpulan produk rencatan asid asetik di bawah tahap rencatan 
pertumbuhan yang dilaporkan sebanyak 2 g.L-1 dan kestabilan plasmid didapati 
berada dalam keadaan baik. Antigen rekombinan BmSXP kemudian ditulenkan 
dalam keadaan tidak ternyahasli (non-denaturing) dengan menggunakan 
kromatografi afiniti tidak bergerak. Demi meningkatkan keberkesanan proses 
penulenan, pelbagai isipadu penimbal basuhan, kepekatan imidazol dan garam 
dilakukan. Didapati kepekatan garam pada 300 mM NaCl dan 30 mM imidazol 
memberikan hasil terbaik, dan bersama dengan 10 isipadu penimbal basuhan telah 
memberikan hasil antigen rekombinan BmSXP yang tertinggi dengan ketulenan yang 
baik. Tindak balas imuno dari antigen rekombinan BmSXP yang dihasilkan 
menunjukkan ia adalah 100% sensitif dan spesifik apabila diuji dengan ELISA dan 
Pemblotan Western menggunakan sampel serum daripada 32 pesakit LF (16 
Wuchereria bancrofti, 16 Brugia malayi) dan 32 serum kawalan yang lain (16 
penyakit nematoda yang lain, 16 individu sihat). Keseluruhan pengeluaran protein 
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sasaran dapat ditingkatkan hampir 20-kali ganda berbanding dengan kaedah 
pengkulturan konvensional di dalam kelalang. Kesimpulannya, kajian ini telah 
memberikan kaedah yang lebih baik, lebih efisien dan menjimatkan kos untuk proses 
pengeluaran dan penulenan protein rekombinan BmSXP. 
 
 xxv 
FERMENTATION OF RECOMBINANT E. coli 
TOP10F’/pPROEX™HTa/BmSXP TO ACHIEVE HIGH YIELD 
OF BIOMASS AND RECOMBINANT ANTIGEN FOR 
DIAGNOSTIC APPLICATION 
 
ABSTRACT 
 
panLF Rapid™ is a rapid IgG4 antibody detection test which is based on the 
detection of anti-filarial IgG4 antibodies that react with recombinant B. malayi 
antigens, BmR1 and BmSXP. This diagnostic kit is very useful for the detection of 
lymphatic filariasis (LF), especially in assisting the WHO on its certification and 
surveillance activities of post-mass drug administration that is in relation to its 
‘Global Programme to Eliminate Lymphatic Filariasis’ effort. The production of this 
test kit has received a significant demand in the market, hence there is a need to up-
scale the production of the recombinant antigens and increase the purification 
efficiency in order to increase the production rate and also reduce the cost of 
production. In this study the yield of BmSXP recombinant antigen was maximized by 
achieving high biomass yield using fed-batch culture in a bioreactor, and the 
recovery rate of the protein of interest was optimized in the downstream purification 
process. The cultivation of the recombinant bacteria 
(TOP10F’/pPROEX™HTa/BmSXP) was initially optimized in small-scale 
fermentation using shake flask culture where it yielded 4.2 g.L-1 and 
0.576 mg.g DCW-1 of BmSXP. The up-scaling process was then performed using fed-
batch fermentation where cells were grown in modified Terrific broth medium and 
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glucose was fed exponentially at a controlled rate using Multifermenter Control 
Software (MFCS) for automated feeding. Varying an assortment of feeding 
strategies, specific growth rate (µ) and induction strategies, biomass concentration of 
19.43 g.L-1 and 11.16 mg.g DCW-1 of BmSXP were obtained based on exponential 
feeding strategy at µ of 0.20 h-1, and with 1 mM single pulse IPTG induction at the 
late-log phase of the bacterial growth curve. It was also observed that at this feeding 
rate, the fermentation yield coefficients of overall specific productivity (YP/X), 
biomass yield (YX/S) and product yield (YP/S) were high. This strategy has 
successfully controlled the accumulation of acetic acid by-inhibitory product below 
the reported growth inhibitory level of 2 g.L-1 and plasmid stability was found to be 
good. The BmSXP recombinant antigen was then purified under non-denaturing 
conditions using immobilized metal affinity chromatography. In order to increase the 
efficiency of the purification process, various volumes of wash buffer, imidazole and 
salt concentrations were performed. Salt at 300 mM and imidazole at 30 mM were 
found to be the best concentrations, and along with 10 column volumes of washing 
buffers gave the best yield of BmSXP recombinant antigen while achieving sufficient 
purity. Immunoreactivity of the recovered BmSXP recombinant antigen was found to 
be 100% sensitive and specific when tested with ELISA and Western blot using 
serum samples from 32 LF patients (16 Wuchereria bancrofti, 16 Brugia malayi) and 
32 other control sera (16 other nematode disease, 16 healthy individuals). The overall 
production of the target protein was improved to almost 20-fold compared to the 
conventional flask cultivation method. In conclusion, this study provided an 
improved, more efficient and cost-saving method for the production and downstream 
processing of BmSXP recombinant protein. 
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CHAPTER I 
 
INTRODUCTION 
 
1.1 Introduction to filariasis 
1.1.1 Lymphatic filariasis 
 
Lymphatic filariasis (LF) or elephantiasis as commonly known, is a parasitic disease 
caused by thread-like filarial nematodes or round worms that live in the human 
lymphatic system. LF is mainly caused by three species of filarial nematodes namely 
Wuchereria bancrofti (W. bancrofti), Brugia malayi (B. malayi) and Brugia timori. 
 
This disease is widespread throughout countries located within the equator band, 
namely the tropical and sub-tropical regions of the world, such as Asia, Africa, 
Central and South America. An estimated 1.3 billion people around the world 
(approximately 19% of world population) are at risk of LF infection. Southern and 
Southeast Asian regions have by far the greatest number of people (891 million) at 
risk for LF (accounting for 68% globally), out of which 454 million people at risk are 
in India alone. Tropical Africa represents the second largest number of people at risk, 
estimated at 382 million in 2007 (30% globally). Currently over 120 million people 
in at least 83 countries are already infected, with more than 51 million in chronic 
stage whereby they have been incapacitated or disfigured with swollen breasts 
(lymphoedema) and genitals (hydrocele) or swollen limbs with thickened, hard, 
rough and fissured skin, a condition known as Elephantiasis (Michael & Bundy, 
1997; Lindsay & Thomas, 2000; Muturi et al., 2008; WHO, 2008; GAELF, 2010). In 
addition to the overt abnormalities, internal damage to the kidneys and lymphatic 
system is a common and hidden problem (Srivastavaa et al., 2010). The economic 
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impact of LF is significant as it is one of the world’s most disabling and disfiguring 
diseases. This disease strikes poverty ridden and underdeveloped countries, hence it 
is also known as the disease of poverty. 
 
In 1998, the World Health Organization (WHO) has identified lymphatic filariasis to 
be one of the six infectious diseases that has the potential to be eliminated as a public 
health problem (WHO, 1998; Ottesen et al., 2008). In response to this, Global 
Programme to Eliminate Lymphatic Filariasis (GPELF) was initiated in year 2000 
with two major objectives to achieve. Firstly is to interrupt transmission of the 
parasite and the other objective is to provide care for those who suffer the 
devastating clinical manifestations of the disease (morbidity control). The ultimate 
ambitious goal of this program is to relegate LF from the world as non-public health 
priorities by year 2020 (Addis & Brady, 2007). 
 
1.1.2 Wuchereria bancrofti 
 
Bancroftian filariasis is caused by W. bancrofti infection and it is responsible for 
90% (115 million) of all LF infections. W. bancrofti largely affects areas across the 
broad equatorial belt (Africa, the Nile Delta, Turkey, India, the East Indies, Southeast 
Asia, Philippines, Oceanic Islands, Australia, and parts of South America). The 
remaining 10% are due to two species of the genus Brugia and occur typically in 
Asia (Figure 1.1) (Michael & Bundy, 1997; Fischer et al., 2004; WHO, 2006).  
 
The adult W. bancrofti male and female worms’ measure 0.2 mm wide and up to 10 
cm long (Figure 1.2).  Mature male and female worms mate in the lymphatic system 
of the definitive host, and females could produce copious numbers of up to 50,000 
microscopic microfilaria (mf) per day, each mf measures 250–300 mm long,
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Figure 1.1  Lymphatic filariasis endemic areas 
Source: WHO (2008) and Manguin et al. (2010) 
3 
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Figure 1.2 Relative sizes of mf developmental stages that occur within 
compatible mosquito hosts: Cyclodevelopmental transmission 
Source: Erickson et al. (2009) 
 
A: Microfilariae are ingested during blood feeding 
B: Parasites differentiate into non-feeding, first-stage larvae within mosquito indirect 
flight muscle cells 
C: Following the first molt, second-stage larvae remain intracellular parasites which 
ingest cellular material into their newly developed digestive tract 
D: Third-stage larvae leave the muscle cells and migrate to the mosquito’s head and 
proboscis where they will exit through the mosquito cuticle during blood feeding 
 5 
8 µm wide. These microscopic mf would then find their way into the blood 
circulation, survive and circulate freely in the blood of the human host for many 
months, possibly longer, while awaiting an opportunity of being picked up by 
mosquitoes and continue their life cycle (Section 1.1.3). Adult worms live for an 
estimated four to six years, but may survive up to 15 years or more with each 
producing ten million of mf in their lifetime (Manguin et al., 2010). 
 
1.1.3 Transmission and life cycle 
 
There are five different stages in the life cycle of lymphatic filaria as depicted in 
Figure 1.3. Filariasis is spread from an infected human whom someone with worms 
in his/her bloodstream to an uninfected human by mosquitoes. More than 70 species 
and subspecies of mosquitoes mainly Anopheles, Aedes, Culex and Mansonia can 
transmit the infection (Stone et al., 1959; Nanduri & Kazura, 1989).  
 
During the blood meal, mosquito vectors ingest mf produced by adult female worms 
found circulating in the peripheral blood. Within 2 hours time, the mf will quickly 
penetrate the midgut epithelium to access the hemocoel (Christensen & Sutherland, 
1984). Mf then migrate in the mosquito’s hemolymph to reach the thoracic 
musculature and from there penetrate into the indirect flight muscles. It is in the 
thoracic muscle tissue where larvae development take place, where mf undergo two 
molts (L1 and L2). After several days, the parasites undergo an additional molt and 
emerge as infective-stage larvae (L3). Approximately 10 to 14 days after exposure 
depending to environmental temperature, the L3 eventually breaks free from the 
flight muscles into the hemocoele and ultimately migrate to the insect’s head lodged 
in or near the labium of the proboscis. When the mosquito returns to blood feed, 
these 1.2–1.6 mm long L3 infective larvae will break through the cuticle or emerge 
 6 
from the tip (labellum) of the mosquito’s labium onto the vertebrate human host skin. 
The parasite is thus indirectly transmitted and must enter the host body via an open 
portal, such as the mosquito bite wound or a nearby break in the skin. 
 
After entering the definitive host body, the L3 is then transported via the lymphatic 
vessels to lymph nodes to begin development (following two intermediate molts) into 
mature adult male or female worms (0.2 mm wide and up to 10 cm long) where they 
mate and the females produce copious numbers of up to 50,000 microscopic mf per 
day (250–300 mm long, 8 mm wide). For W. bancrofti it takes a period of four to 15 
months (possibly longer) before the appearance of mf in the peripheral blood. Adult 
worms live for an estimated four to six years, but may survive up to 15 years or more 
with each producing ten of millions of mf in their lifetime. Mf are believed to survive 
and circulate freely in the blood of the human host for many months, while awaiting 
an opportunity of being picked up by mosquitoes (Erickson et al., 2009). 
 
1.1.4 Clinical manifestation 
 
Although infection from bancroftian filariasis is not fatal, it is considered a leading 
cause of infirmity, permanent disability and chronic morbidity, often resulting in 
societal stigma of disfigured victims (Figure 1.4). 
 
There are two types of clinical manifestation, namely: lymphatic filariasis (presence 
of adult worms) and occult filariasis (immuno hyper responsiveness). In LF  clinical  
manisfestation, it could further sub-categorized into 4 stages, namely: asymptomatic 
amicrofilaraemia stage, asymptomatic microfilaraemia stage, stage of acute 
manifestation and stage of obstructive (chronic) lesions. 
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Figure 1.3 The life cycle of W. bancrofti 
Source: Life Cycle of Wuchereria bancrofti (2010)  
 
 
Figure 1.4 Elephantiasis (lymphoedema) of lower limb 
Source: Wuchereria bancrofti (2010) 
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Asymptomatic microfilaraemia individuals are the infected people who do not 
exhibit any physicals symptom for months and years, even though they have 
circulating mf making them an important source of infection. Individual with acute 
symptoms may experience fever, chill, malaise, headache and vomiting. It may take 
10-15 years to reach the chronic (obstructive) lesions stage whereby lymphoedema 
occurs, resulting in temporary or permanent infirmity. This is due to the permanent 
damage to the lymph vessels caused by the adult worms. Elephantiasis, is the result 
of lymphoedema of the extremities, and frequently associated with 
lymphadenopathy, lymphangitis, hydrocoele (in males) and chyluria (Crompton & 
Savioli, 2007).  This often led to painful and gross enlargement of the legs 
(Figure 1.4) and arms, the genitals, vulva and mammary glands. 
 
Occult or cryptic filariasis is a classical clinical manifestation in which mf will not be 
present. Occult filariasis is believed to be the result of hyper responsiveness to 
filarial antigens derived from mf (seen more in males). Patients present symptoms 
with paroxysmal cough and wheezing, low grade fever, scandy sputum with 
occasional haemoptysis, adenopathy and increased eosinophilia (Ganesh, 2010). 
 
1.1.5 Diagnosis of lymphatic filariasis 
 
Diagnostic tools are important to GPELF because they affect decisions on where to 
distribute mass drug administration (MDA), how to measure its effectiveness, how to 
define targets and endpoints for stopping MDA and how to monitor populations for 
resurgence of LF transmission following suspension of MDA (WHO, 2005). 
 
The standard method for diagnosing active infection is the identification of mf in a 
blood smear by microscopic examination. There are three variants of W. bancrofti 
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recognized on periodicity patterns of circulating mf found in peripheral blood of 
humans, namely: the nocturnal periodic (NP), nocturnal subperiodic (NSP) and 
diurnal subperiodic (DSP) forms. Periodicity is based on the prevailing circadian 
distribution of mf in the peripheral blood. NP form presents the majority of mf by 
night (peak periodicity at 2200 hours to 0300 hours) with very few observable by day 
as they sequester in the lungs. The two subperiodic forms (NSP and DSP) are far 
more restricted in distribution (Figure 1.1) and are present in the peripheral blood 24 
hours a day with peak densities typically seen in the late afternoon and early evening 
hours (1800 hours to 2000 hours) (Gould et al., 1982). Since most prevalent LF 
endemic areas consist of mf in NP variant, blood collection should be done at night 
to coincide with the appearance of the mf. A thick blood smear is made by spreading 
a drop of blood onto the slide, dried and stained with Giemsa or hematoxylin and 
eosin, before examining the prepared slide under the microscope for the presence of 
mf. The advantages of thick blood smear technique are specificity, inexpensive and 
requires little infrastructure. However, this method is insensitive for active infections 
as it misses people with low mf counts and those with amicrofilaremic infections 
who are individuals that have the potential to contribute to future transmission. In 
addition, night blood collection do not have the desirable features in practice because 
proper sampling of populations, preparation of smears, staining and microscopy are 
labor intensive is troublesome to both the staff and villagers and impractical in some 
endemic areas (Weil & Ramzy, 2007). For increased sensitivity, concentration 
techniques can be used. 
 
In the not-so-distant past, diagnostic tools for LF were limited to clinical examination 
and the detection of mf. However, with the recent advances in filarial diagnostics 
over the years, molecular diagnostic tools such as sensitive PCR assays have been 
 10 
developed to detect DNA of lymphatic filarial parasites in humans and in mosquito 
vectors (Fisher et al., 2002). Although rapid methods for the detection of PCR 
products have been established (Fisher et al., 2002 & Klüber et al., 2001), the main 
obstacles preventing its practice is that PCR assays require a sophisticated laboratory 
infrastructure and trained skilled personnel to perform the analysis. PCR assays also 
require long running time up to several hours prior to data collection, thus it is not 
practical to be used with large number of samples and for field screening. In 
addition, PCR generally do not detect people with amicrofilaraemic infection. 
 
Another detection method is the usage of ultrasonography whereby it uses a 7.5 MHz 
or 10 MHz probe to locate and visualize the movements of living adult worms of W. 
bancrofti in the lymphatic vessels of asymptomatic males with microfilaraemia, also 
known as the search for the ‘filarial dance sign’. However, this technique is not 
suitable for large scale studies, and it is not very useful for brugian filariasis 
diagnosis in which the adult worms are not found in the peripheral lymphatics. 
 
Lymphoscintigraphy is another known technique used to diagnose LF. The structure 
and function of the lymphatics of the involved limbs are assessed by 
lymphoscintigraphy through the injection of radio-labelled albumin or dextran in the 
web space of the toes. The structural changes are then imaged using a Gamma 
camera. Lymphatic dilation and obstruction can be directly demonstrated even in 
early clinically asymptomatic stage of the disease. However, the disadvantage of this 
technique is again the requirement of a sophisticated laboratory infrastructure and 
trained skilled personnel to perform the analysis. 
 
Last but not least, immunoassays detect the presence of specific antigens or 
antibodies in the blood of individuals. Rapid tests kits such as antibody-based 
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detection test kits are now commercially available to detect brugian filariasis 
(Rahmah et al., 2003), bancroftian filariasis (Weil et al., 1997) and both kinds of 
filariasis (Rahmah et al., 2007). To-date, this technique has shown tremendous 
potential in field application as the preferred diagnostic method of filarial infection 
attributed by its features of not requiring blood sampling at certain time of the day, 
high sensitivity and specificity, rapid (approximately 15 minutes to reading), and 
user friendliness. Immunoassays have performed their function well as the diagnostic 
tools used to assist and facilitate surveillance activities in monitoring the control 
efforts, and to evaluate new drugs. 
 
1.1.6 Elimination of filariasis 
 
The World Health Organization (WHO) has identified LF to be one of the six 
infectious diseases that has the potential to be eliminated as a public health problem 
(WHO, 1998; Ottesen et al., 2008). This would be done using selective diagnosis to 
identify endemic areas followed by repeated cycles of MDA to reduce both infection 
prevalence and transmission rates to levels below those required for sustained 
transmission (Ottesen et al., 1997; Molyneux, 2001; Ottesen, 2006). In this case, a 
single dose of two drugs regimens has being advocated (albendazole 400 mg plus 
diethylcarbamazine (DEC) 6 mg.kg-1, or albendazole 400 mg.kg-1 plus ivermectin 
200 µg.kg-1 for a period of 4-6 years corresponding to the reproductive life span of 
the parasite (Ottesen, 2000). 
 
In response to this, the Global Alliance to Eliminate Lymphatic Filariasis (GAELF) 
was formed in the year 2000, with the sole purpose of supporting GPELF based on 
MDA. This programme aims to eliminate LF by interrupting the transmission of 
infection and to alleviate and prevent both suffering as well as disability caused by 
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the disease. The principal strategy for the latter focuses on decreasing the secondary 
bacterial and fungal infection of limbs and genitals (Ottesen, 2000). The ultimate 
ambitious goal of this program is to relegate LF from the world as non-public health 
priorities by year 2020 (Addis & Brady, 2007). With a target population of 1.3 
billion people, GPELF is the largest infectious disease intervention based on MDA 
initiated to date (WHO, 2008).  
 
Mapping and surveillance studies play a determining role in the success of GPELF. 
LF endemic areas need to be identified in order to allow repeated cycles of MDA to 
be carried out to reduce both infection prevalence and transmission rates to levels 
below those required for sustained transmission (Ottesen et al., 1997; Molyneux, 
2001; Ottesen, 2006). Hence, sensitive and specific diagnostic tools are required to 
assist and facilitate mapping and surveillance activities in monitoring the control 
efforts of the programme. 
 
1.1.7 panLF Rapid™ 
 
Since most of the endemic areas (Figure 1.1) reside in areas which are remote and/or 
without adequate health and laboratory facilities, therefore a rapid and field 
applicable diagnostic test, particularly those based on immunochromatography 
technology, are most suitable to be employed for the GPELF to ensure that it can be 
performed easily by field workers while also giving reliable and reproducible results. 
 
Immunochromatography have became the most practical field applicable solution 
due to its attributes of easy on-site testing, followed by rapid, simple reading and 
interpretation of results. These features would avoid potential logistical challenges 
for sample storage and transportation, as well as more serious problems such as 
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sample mix-up due to unclear/unreadable labels and sample degradation that may 
occur if collection and performance of tests are not conducted at the same or nearby 
locations (Rahmah et al., 2007). 
 
panLF Rapid™ (Figure 1.5) is a rapid immunochromatographic test strip that utilizes 
BmSXP and BmR1 recombinant antigens for the detection of specific IgG4 antibodies 
against LF parasites of both bancroftian and brugian filariasis (Rahmah et al., 2007). 
The test strip consists of three lines namely two test lines, one comprising BmSXP 
and the other BmR1 recombinant antigens, and a final control line. Goat anti-mouse 
IgG antibody is employed in the control line. Serum/plasma and whole blood are 
employed as test samples. These test lines are invisible in an unused test and are 
coloured red after performance of the test due to the reaction between the anti-filarial 
antibodies in patient sera with the colloidal gold conjugated monoclonal anti-human 
IgG4. The test is performed by delivering 25 µl serum sample into the square bottom 
well of the test strip. When the sample front reaches the blue line on the cassette 
window, two drops of buffer are then added to the top oval well to release the 
conjugate solution (monoclonal anti-human IgG4 conjugated to colloidal gold). This 
is followed by pulling a plastic tab at the bottom of the cassette and adding a drop of 
buffer into the square bottom well. The results are then ready to be read 15 minutes 
later. If only one red band appeared at the control line, this denotes a negative result. 
A test is interpreted as positive when either three red lines (two test lines and a 
control line) or two red lines (a test and a control line) are observed (Rahmah et al., 
2007; MBDr, 2010). 
 
BmSXP is a recombinant antigen derived from SXP1 gene [GenBank no: M98813]. 
The clone was isolated from a B. malayi adult male worm cDNA library with sera of  
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Figure 1.5 panLF Rapid™ rapid immunochromatographic diagnostic kit for the 
detection of both bancroftian and brugian filariasis infection 
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bancroftian filariasis patients (Dissanayake et al., 1992). A rapid flow-through IgG  
immunofiltration test using WbSXP recombinant antigen has been developed and a 
sensitivity of 91% (30/33) was recorded for detection of W. bancrofti infection 
(Lammie et al., 2004). The other recombinant antigen, BmR1 which was derived 
from Bm17DIII gene [GenBank: AF225296] has shown to be highly sensitive 
(>95%) and specific (≥ 99%) for the detection of B. malayi and B. timori infections 
in laboratory evaluations (Rahmah et al., 2003; Lammie et al., 2004; Fischer et al., 
2005) and field studies (Supali et al., 2004; Jamail et al., 2005; Melrose & Rahmah, 
2006). BmSXP was found to be more sensitive (95%) in detecting W. bancrofti 
infection as compared to BmR1 (14%). On the other hand BmR1 was more sensitive 
than BmSXP in detecting B. malayi infection (98% and 84% respectively) (Rohana et 
al., 2007). Since BmR1 and BmSXP recombinant antigen cross-reacts with 
bancroftian and brugian filaria infection sera respectively, the panLF Rapid™ test is 
not useful for species identification. However in the context of GPELF, this does not 
pose a problem. When both recombinant antigens were applied to the panLF Rapid™ 
test strip, a multicenter evaluation conducted in 2007, has shown an average overall 
sensitivity of 96.5% (390/404); with the sensitivity for the detection of W. bancrofti 
infection at 96.0% (217/226), while the detection of brugian filariasis was 97.2% 
(173/178). Average specificities of 99.6% were recorded when evaluated with serum 
samples from a large variety of other infections, which included helminthes, 
protozoan, bacterial and viral infections (Rahmah et al., 2007). 
 
In the pre-certification phase of the elimination program and in the surveillance 
activities post-elimination, a highly sensitive test as displayed by an antibody-based 
diagnostic tool is essential since the level of infection (if any) is very low. Therefore, 
although a rapid antigen detection test is already available for bancroftian filariasis, 
 16 
an antibody detection assay would probably be more useful in the screening of young 
children as required in the precertification phase of GPELF. Antigen detection assays 
depend on the presence of developmentally mature worms while antibody assays 
could potentially detect exposure to infective larvae by children. 
 
A rapid test such as panLF rapid™ would be very useful in several kinds of 
situations, namely testing in areas where there are mixed bancroftian and brugian 
filaria infections, in areas where the infecting species is not known or not confirmed, 
and for screening of immigrant workers in countries such as Malaysia which has 
more than 1.3 million workers from filarial endemic countries. These workers may 
pose a threat to the achievement of the disease elimination or they may be a source of 
resurgence of the disease in the future (Rahmah et al., 2007). 
 
1.2 E. coli fermentation 
1.2.1 Introduction 
 
Industrial microbiology is where microorganisms are put to work in order to yield a 
product. Fermentation is an important part of industrial microbiology, and it is 
defined as the process of deriving energy from the oxidation of organic compounds 
via an electron transport chain (Klein et al., 2004). In general, fermentation involves 
the breaking down of complex organic substances into simpler ones. The microbial 
or animal cell obtains energy through glycolysis, splitting a sugar molecule and 
removing electrons from the molecule. The electrons are then passed to an organic 
molecule such as pyruvic acid. This results in the formation of a waste product that is 
excreted from the cell, such as ethyl alcohol, butyl alcohol, lactic acid, and acetone. 
Nevertheless, the saying goes: “One man’s trash is another man’s gold”. The 
unwanted waste product from the cultured cells is then harvested and purified into 
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valuable industrial products which would then be sold to the supply chain. To-date, it 
is now the primary method of bioproduction in the biotechnology industry. 
 
Escherichia coli (E. coli) has been the preferred “workhorse” for the production of 
recombinant proteins as it is the best characterized prokaryotic host in terms of 
molecular genetics, physiology, and expression system (Makrides, 1996; Choi & 
Lee, 2004; Choi et al., 2006). These attributes contributed in it being selected as one 
of the pioneer organisms chosen for large scale fermentation studies.  
 
Exploring the growth limits of microorganisms in general and E. coli in particular, 
engaged industrial microbiologists many years before it was possible to convert 
E. coli to a “production machine” for heterologous proteins. Early studies on high 
cell density growth of E. coli were performed either to investigate the limits of 
bacterial growth in liquid cultures (Gerhardt & Gallup, 1963) or to obtain large 
quantities of exponentially grown E. coli needed for biochemical studies (Bauer & 
Ziv, 1976). During the 1980s, when much information on the genetics and 
physiology of the bacterium accumulated and E. coli became the obvious organism 
of choice for recombinant protein production (Lee, 1996), much more emphasis was 
put on its high-density growth. Since then, numerous methods to obtain high-density 
cultures have been developed, each aiming at providing means to bypass the 
physiological constrains that prevent bacteria from growing to the limit of physical 
barriers between solid state and liquid suspension of cells (Shiloach & Fass, 2005). 
 
Large scale fermentation in bioreactors of all sizes has been employed for the 
purpose of increasing volumetric productivity of the cultured E. coli by achieving 
high cell density culture. In addition, other advantages of bioreactor fermentation 
technology are increased cost-effectiveness, reduced culture volume, enhanced 
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downstream processing, reduced wastewater, lower production cost and a reduced 
investment in equipment (Choi et al., 2006). The development of this technique for 
E. coli has facilitated the production of recombinant proteins and non-protein 
biomolecular products such as amino acids, primary and secondary metabolites with 
high productivities (Jeong & Lee, 1999; Gerigk et al., 2002; Choi et al., 2006). 
 
1.2.2 Recombinant protein production in E. coli 
 
Escherichia coli (E. coli) is a Gram negative, rod-shaped bacterium that is commonly 
found in the lower intestine of warm-blooded organisms (endotherms). E. coli has 
been the most frequently employed host due to the vast availability of numerous 
expression systems designed for producing recombinant proteins (Makrides, 1996). 
In addition, the bacteria can also be grown easily and its genetics are comparatively 
simple and easily manipulated or duplicated through a process of metagenics, 
making it one of the best-studied prokaryotic model organisms for biotechnology and 
microbiology. The many advantages of E. coli have ensured that it remains a 
valuable organism for the high-level production of recombinant proteins (Gold, 
1990; Hodgson, 1993; Olins & Lee, 1993; Shatzman, 1995; Georgiou & Valax, 
1996). 
 
However, in spite of the extensive knowledge on the genetics and molecular biology 
of E. coli, not every gene can be expressed efficiently in this organism. This may be 
due to the unique and subtle structural features of the gene sequence, the stability and 
translational efficiency of mRNA, the ease of protein folding, degradation of the 
protein by host cell proteases, major differences in codon usage between the foreign 
gene and native E. coli, and the potential toxicity of the protein to the host. 
Moreover, the major drawbacks of E. coli as an expression system include the 
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inability to perform many of the post-translational modifications found in eukaryotic 
proteins, the lack of a secretion mechanism for the efficient release of protein into the 
culture medium, and the limited ability to facilitate extensive disulfide bond 
formation (Makrides, 1996). In addition, the stability of foreign proteins produced in 
E. coli can be low due to proteolytic degradation, and overexpressed proteins are 
often produced in the form of inclusion bodies, which later require complicated and 
costly denaturation and refolding processes to make them functional. 
 
A variety of techniques including the use of different promoters and host strains, 
coexpression of chaperones and changing cultivation conditions have been employed 
to solve some of these problems. In addition, researchers have developed various 
methods to direct recombinant proteins to different cellular compartments (Makrides, 
1996; Choi & Lee, 2004). Figure 1.6 summarizes various strategies employed for the 
production of recombinant proteins in E. coli. 
 
E. coli cells consist of inner and outer membranes that divide the organism into three 
compartments: the cytoplasm, the periplasm and the extracellular space, out of which 
the recombinant proteins can be targeted to one of these compartments. The choice 
of an expression system for high-level production of recombinant proteins depends 
on many factors such as cell growth characteristics, expression levels, intracellular 
and extracellular production, and the biological activity of the target protein. In 
addition, each expression system has specific costs in terms of process, design, and 
other economic considerations (Choi et al., 2006). The decision to target 
recombinant proteins to the cytoplasmic space, periplasmic space or culture medium 
depends on balancing the advantages and disadvantages of each compartment as 
tabulated in Table 1.1. 
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Figure 1.6 Strategies for the production of recombinant proteins in E. coli 
Source: Choi et al. (2006) 
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Table 1.1 Advantages and disadvantages of protein production at different 
compartments of E. coli 
 
 Advantages Disadvantages 
Cytosolic 
production 
- Higher protein yield. 
- Simple plasmid construct. 
- Inclusion body, thus easy 
purification, protection from 
proteases, and inactive protein 
(non-toxic). 
- N-terminal extension. 
- No disulfide bond formation. 
- Complex purification (soluble 
form). 
- Inclusion body, hence protein 
folding, and denaturation or 
refolding processing steps are 
required. 
- May expose to protease 
degradation. 
Secretory 
production 
- Simple purification. 
- Improved folding. 
- N-terminal authenticity. 
- Soluble protein production. 
- Prevention from protease 
degradation. 
- Inclusion body may form. 
- Improper cleavage of signal 
sequence. 
- Cell lysis. 
Excretory 
production 
- Simple purification. 
- Improved folding. 
- N-terminal authenticity. 
- Soluble protein production. 
- Prevention from protease 
degradation. 
- Cell lysis. 
- No excretion usually. 
- Low protein yield. 
- Dilution of product. 
 
Source: Choi et al. (2006) 
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Many research groups have focused on the secretory production system to target the 
recombinant protein production into the periplasmic space based on some exclusive 
characteristics (Choi & Lee, 2004; Choi et al., 2006). Firstly is that the N-terminal 
amino acid residue of the secreted product can be identical to that of the naturally 
secreted gene product, as the signal sequence can be cleaved away by signal 
peptidases. Second, protease activity is considered to be much lower in the 
periplasmic space than in the cytoplasm, therefore protein degradation becomes less 
of an issue. Thirdly, the purification of the recombinant protein could be simplified 
as the periplasm contains far fewer native host proteins. Finally, correct formation of 
disulfide bonds can be facilitated because the periplasmic space provides the 
necessary oxidative environment (Hockney, 1994; Makrides, 1996). 
 
1.2.3 Small scale fermentation using shake flask culture 
 
In process development and optimization in biotechnological industry, shake flasks 
are small scale reactors of extremely simple mechanical design. They are 
inexpensive and easy to operate, require only small amounts of material and power, 
and allow a large number of cultivations to be carried out in parallel (Peter et al., 
2006). Due to these attributes, they are primarily used at the early stages of process 
development, where very decisive experiments are performed. Through the usage of 
statistically well-designed experiments, shake flask cultures can be harvested and 
analyzed in large numbers with relative ease, therefore greatly facilitating process 
optimization (Gerson & Kole, 2001). At this stage, controlled and reproducible 
experimental conditions are essential in order to ensure that the correct optimized 
parameters are precisely transferred to the up scaling process of bioreactor 
fermentation (Freedman, 1970). 
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1.2.4 Large scale fermentation using bioreactor 
 
A bioreactor may refer to any device or system that supports a biologically active 
environment. This system is where a chemical process is carried out by organisms, in 
which biochemically active substances are then derived from such organisms. 
Bioreactors are widely used for industrial production of microbial, animal and plant 
metabolites. The process can either be performed under aerobic or anaerobic 
conditions. These bioreactors are commonly cylindrical, ranging in size from liters to 
cubic meters, and are often made of glass or stainless steel. They can be further 
subcategorized into several different types, namely stirred-tank reactor (STR), air-lift 
fermenter (ALF), dialysis reactor, and chemostat (Takayama & Akita, 1994). In the 
field of pharmaceutical industry, STR type bioreactor is the preferred conventional 
mixing vessel frequently used for industrial application. 
 
The components that made up STR (Figure 1.7) basically consist of an impeller, 
baffles, sparger, and various sensors to detect the conditions of namely pH, 
temperature, and DO. The impeller functions to stir and mix the culture, causing high 
turbulence and the formation of a central vortex in the process, in which it is broken 
down by the baffles that functions to provide a uniform liquid flow. The sparger, 
which is located directly at the bottom of the impeller shaft functions to break down 
the inflow aeration into tiny air bubbles that have high surface area over volume ratio 
in order to provide maximum air transfer rate between the air bubble and the culture. 
The fitted sensor accessories monitor the culture condition in terms of pH, 
temperature and DO. The pH condition is controlled by the automated addition of 
either acid or base to achieve the desired set point. The temperature in the vessel is 
controlled by removing heat with the means of water circulating through a 
double-jacketed  system.  As  for  the  DO percentage,  it  could  be  controlled  by the  
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Figure 1.7  Schematic diagram of a stirred-tank reactor (STR) 
Source: Microorganisms and Disease Booklet (2010) 
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application of a cascading system which revs up the stirring speed of the impeller, 
increasing the aeration or through direct injection of pure oxygen. In addition to all 
these accessories, a port inlet is usually used by the inoculum to inoculate and start 
the fermentation process. 
 
The monitoring and controlling of a fermentation running process can be 
commanded with the assistance of a computer software. In this study, a 5 L 
bioreactor (Biostat B5, B. Braun Biotech International, Germany) was used to carry 
out the whole experiment. This bioreactor comes with the Multifermenter Control 
System Software (MFCS) which functions to collect real-time data points throughout 
the fermentation process, and also to act as the command center that navigates the 
bioreactor settings, as well as the controlling of the automated feeding system. In 
other words, MFCS allows the monitoring and controlling of substrate feeding into 
the culture. As it name implies, the MFCS is also capable of controlling multiple 
units of bioreactors at any given time. To hook up the bioreactor with the MFCS, a 
PC installed with the MFCS-Win software is used as the software interface which 
allows data exchange between the bioreactor’s DCU via a local network cable. 
Additional sensor accessories are fitted to monitor the culture condition in terms of 
pH, temperature, DO, and peristaltic pumps for substrate feeding, as well as pH 
control. Figure 1.8 shows the example of instrument setup for a typical fermentation 
process.
